Stockscreener 앱 받기
42.33
0.57%
0.24
시간 외 거래:
42.33
Qiagen Nv 주식(QGEN)의 최신 뉴스
Massachusetts Financial Services Co. MA Sells 79,145 Shares of Qiagen (NYSE:QGEN) - MarketBeat
Jennison Associates LLC Boosts Holdings in Qiagen (NYSE:QGEN) - MarketBeat
QIAGEN NV : Jefferies is Neutral - Marketscreener.com
Qiagen (NYSE:QGEN) Stake Lowered by Nuance Investments LLC - MarketBeat
QIAGEN Stock Flat Post Q3 Earnings & Revenue Beat, 2024 EPS View Up - MSN
Analysts Set Qiagen (NYSE:QGEN) Price Target at $50.88 - MarketBeat
Qiagen (NYSE:QGEN) Shares Bought by Natixis Advisors LLC - MarketBeat
180,729 Shares in Qiagen (NYSE:QGEN) Purchased by Impax Asset Management Group plc - MarketBeat
QGEN Collaborates With McGill University Centre: Stock to Gain? - Yahoo Finance
Victory Capital Management Inc. Has $117.33 Million Stock Position in Qiagen (NYSE:QGEN) - MarketBeat
What is William Blair's Estimate for Qiagen FY2024 Earnings? - MarketBeat
Crossmark Global Holdings Inc. Sells 12,133 Shares of Qiagen (NYSE:QGEN) - MarketBeat
Pharmahungary Group participates in ambitious EU EVEREST Project - European Biotechnology News
QIAGEN collaborates with McGill University to advance microbiome research - GlobeNewswire
QIAGEN Partners with McGill to Target $1.8B Microbiome Market in Major Research Deal | QGEN Stock News - StockTitan
Don't Overlook Qiagen (QGEN) International Revenue Trends While Assessing the Stock - Yahoo Finance
QIAGEN NV : UBS reiterates its Neutral rating - Marketscreener.com
Earnings call: QIAGEN tops Q3 expectations, raises 2024 EPS outlook - Investing.com India
Earnings call: QIAGEN tops Q3 expectations, raises 2024 EPS outlook By Investing.com - Investing.com Australia
Qiagen Non-GAAP EPS of $0.46 beats by $0.02, revenue of $459M beats by $2.09M - MSN
Wellington Management Group LLP's Strategic Acquisition of Qiage - GuruFocus.com
Why Qiagen (QGEN) is a Top Value Stock for the Long-Term - Yahoo Finance
Qiagen NV (QGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements - GuruFocus.com
Qiagen Reports Strong Q3 2024 Growth - TipRanks
Is There An Opportunity With Qiagen N.V.'s (NYSE:QGEN) 31% Undervaluation? - Yahoo Finance
QIAGEN NV : Deutsche Bank reaffirms its Buy rating - Marketscreener.com
Qiagen Q3 24 Earnings Conference Call At 9:30 AM ET - Nasdaq
QIAGEN : Markets hailed the Q3 beat + the profitability upgrade - Marketscreener.com
QIAGEN NV : Receives a Buy rating from Berenberg - Marketscreener.com
Qiagen (NYSE:QGEN) Shares Sold by Van ECK Associates Corp - MarketBeat
Qiagen N : QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full year 2024 adjusted EPS outlook - Marketscreener.com
QIAGEN NV : UBS reaffirms its Neutral rating - Marketscreener.com
Qiagen N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Compared to Estimates, Qiagen (QGEN) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Qiagen (QGEN) Q3 Earnings and Revenues Top Estimates - Yahoo Finance
Diagnostics firm Qiagen reports rise in third-quarter revenue - Reuters
QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook - The Manila Times
QIAGEN Q3 Earnings Surge: Sales Hit $502M, Boosts 2024 EPS Outlook | QGEN Stock News - StockTitan
Qiagen NV (QGEN) Q3 2024: Everything You Need to Know Ahead of E - GuruFocus.com
FDA clears fourth Qiagen test in 2024 - BioWorld Online
Qiagen NV (QGEN) Q3 2024 Earnings Report Preview: What to Expect - GuruFocus.com
QGEN Stock Set to Gain From FDA's Clearance of QIAstat-Dx Mini Panel - Yahoo Finance
Qiagen (QGEN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance
QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics - GlobeNewswire
Qiagen Receives FDA Clearance Of Qiastat-Dx Meningitis/Encephalitis Panel To Support Emergency Diagnostics - XM
Forsta AP Fonden Sells 18,586 Shares of Qiagen (NYSE:QGEN) - MarketBeat
Qiagen (QGEN) Set to Announce Earnings on Wednesday - MarketBeat
Raymond James & Associates Trims Position in Qiagen (NYSE:QGEN) - MarketBeat
Global Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030 | DelveInsight - GlobeNewswire Inc.
QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment - GlobeNewswire
0.98%
0.01%
자본화:
|
볼륨(24시간):